HC Andersen Capital: Pharma Equity Group – Lifescience investment company with twofold strategy

The investment case is driven by PEG’s ability to successfully implement and follow a twofold strategy: firstly, to create value by traditional medical development of the pipeline of projects for the individual indications in Reponex. Secondly, to create value via its unique repositioning and reformulation strategy, where already established medical formulas are being used to find new indications, new ways of delivery mechanisms, or new combinations with other established products. The idea is to utilize already available data regarding efficacy, toxicity, and safety, saving both time and money to bring products to market.

Read the full one-pager here.

This is a press release from HC ANDERSEN CAPITAL www.hcandersencapital.dk.

Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a Digital IR / Corporate Visibility subscription agreement.

HC ANDERSEN CAPITAL
Claus Thestrup,
CEO Sweden
[email protected]